title: [Update on current care guidelines. Parkinson's disease].
abstract: Following the diagnosis of Parkinson's disease, treatment may be initiated with MAO-B-inhibitor, even prior to the development of any functional deficit. For patients with a functional deficit who are younger (usually under 75 years of age) and otherwise in good condition, treatment should be started with a dopamine agonist or MAO-B-inhibitor. In other patients, initial treatment with levodopa is recommended. In the case of difficult on-off-symptoms and dyskinesias in spite of optimal treatment, surgical procedures and duodenal levodopa infusion should be considered. Rehabilitation should be targeted at specific problems associated with functional skills.
authors.forename: Marttila
authors.initials: M
authors.lastname: Reijo
authors.forename: Sari
authors.initials: S
authors.lastname: Atula
authors.forename: Esa
authors.initials: E
authors.lastname: Heikkinen
authors.forename: Marja-Riitta
authors.initials: MR
authors.lastname: Jaakkola
authors.forename: Jousilahti
authors.initials: J
authors.lastname: Pekka
authors.forename: Tapani
authors.initials: T
authors.lastname: Keränen
authors.forename: Kirsti
authors.initials: K
authors.lastname: Martikainen
authors.forename: Eero
authors.initials: E
authors.lastname: Pekkonen
authors.forename: Kyösti
authors.initials: K
authors.lastname: Sotaniemi
mesh_terms: D000367:Age Factors; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000627:therapeutic use; D020820:Dyskinesias / Q000188:drug therapy; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D017410:Practice Guidelines as Topic
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D007980:Levodopa